OSUR Overview

OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.

Wall Street analysts forecast OSUR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSUR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

OraSure Technologies Inc revenue for the last quarter amounts to 27.93M USD, decreased -6.70

OraSure Technologies Inc. EPS for the last quarter amounts to -0.32 USD, increased 52.38

OraSure Technologies Inc (OSUR) has 500 emplpoyees as of May 10 2026.

Today OSUR has the market capitalization of 210.68M USD.